Galectin Therapeutics Highlights Outcome Of Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study

4/9/24 9:26:30 AM ET

$GALT

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $GALT alert in real time by email

Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunction-associated steatohepatitis (MASH) liver cirrhosis
Fifth positive recommendation further supports favorable tolerability and safety profile of belapectin
Interim Phase 2b efficacy readout anticipated in Q4 2024

Get the next $GALT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GALT

Date	Price Target	Rating	Analyst

More analyst ratings

$GALT
Market Insights

Live Market Insights

Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by over 50 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Bespoke Extracts The Trade: Bespoke Extracts, Inc. (OTC:BSPK) CEO Michael Feinsod bought a total of 3,000 shares at an average price of $0.07. To acquire these shares, it cost around $210. What's Happening: The company's stock jumped around 51% o
7/24/24 7:03:14 AM ET
$GALT
$RCG
Biotechnology: Pharmaceutical Preparations
Health Care
Investment Managers
Finance
Insider Analysis: Purchase at Galectin Therapeutics Inc. on Jun 20
Recently, on June 20, 2024, Galectin Therapeutics Inc. saw an insider purchase by Director Freeman Kevin D. He bought $5,950 worth of shares, which amounted to 2,500 units at a price of $2.38 per share. This transaction increased his direct ownership by 10% to 28,469 units, as reported in the SEC Form 4. It's essential to analyze this insider purchase in the context of previous transactions within the company. On February 7, 2024, Uihlein Richard E was granted 23,256 shares, increasing his direct ownership by 0.23% to 10,268,751 units. Similarly, on the same date, Zordani Richard A. Jr. filed an SEC Form 4. Continuing the trend, a new insider, Carson Benjamin Sr, filed an SEC Form 3 on Febr
6/20/24 6:44:03 PM ET
$GALT
Biotechnology: Pharmaceutical Preparations
Health Care
As Of March 31, 2024, Galectin Therapeutics Had $23.6M Of Cash And Cash Equivalents. Additionally, The Company Has $10M Remaining Available Under A $60M Line Of Credit Expected To Provide Cash Runway Into May 2025
5/15/24 8:02:19 AM ET
$GALT
Biotechnology: Pharmaceutical Preparations
Health Care

$GALT
Press Releases

Fastest customizable press release news feed in the world

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended September 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "This past quarter, we remained laser-focus on advancing the NAVIGATE trial of belapectin in patients with MASH cirrhosis. As we eagerly await the topline results next month, we remain hopeful that belapectin may be a potential new treatment for the large number of patients in the U.S.
11/14/24 8:00:00 AM ET
$GALT
Biotechnology: Pharmaceutical Preparations
Health Care
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
NORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright MASH Investor Conference being held October 7, 2024. Dr. Jamil will be sharing the latest updates on clinical programs and pipeline advancement on October 7, 2024 at 10:00 AM ET. The webcast of the presentation can be accessed here or through the Company's website on the Events & Presentation page of the investors section. About Galectin TherapeuticsGalectin Therapeutics is dedicated to d
9/30/24 8:00:00 AM ET
$GALT
Biotechnology: Pharmaceutical Preparations
Health Care
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY. Dr. Jamil will be providing a company presentation on September 9, 2024 at 12:00 PM ET. The webcast of the presentation can be accessed here or through the Company's website on the Events & Presentation page of the investors section. Additionally, Galectin management team will be available for on
9/3/24 8:30:00 AM ET
$GALT
Biotechnology: Pharmaceutical Preparations
Health Care

$GALT
Leadership Updates

Live Leadership Updates

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to Chief Medical Officer effective immediately. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "We are very excited to elevate Dr. Jamil to Chief Medical Officer. After joining us in March 2024 as Vice President Clinical Development and Medical Director, Khurram has quickly integrated himself into our team and has led the management of our NAVIGATE clinical trial of belapectin
8/1/24 8:00:00 AM ET
$GALT
Biotechnology: Pharmaceutical Preparations
Health Care
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry. "We are pleased to welcome Khurram to the Galectin team at such a meaningful time of our development program" said Pol F. Boudes, M.D., Chief Medical Officer. "His breadth of expertise in clinical development, especially in hepatology and liver cirrhosis, along with his experience with regulatory interactions a
3/12/24 8:00:00 AM ET
$GALT
Biotechnology: Pharmaceutical Preparations
Health Care
Galectin Therapeutics Strengthens Leadership Team with Strategic Hires to Advance Programs in Cancer Immunotherapy and NASH Cirrhosis
NORCROSS, Ga., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has recently expanded its management team with multiple key leadership appointments, including Dakshina Reddy, MSM, as Executive Director, Regulatory Affairs; Ezra R. Lowe, Ph.D., as Executive Director, Clinical and Preclinical Pharmacology; Marla Mills-Wilson as Executive Director, Clinical Operations; and Jessica Kopaczewski as Associate Director, Clinical Operations. These strategic appointments strengthen the company's clinical, regulatory, and operational efforts across its ongoing programs in c
8/30/21 8:00:00 AM ET
$GALT
Biotechnology: Pharmaceutical Preparations
Health Care

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended September 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "This past quarter, we remained laser-focus on advancing the NAVIGATE trial of belapectin in patients with MASH cirrhosis. As we eagerly await the topline results next month, we remain hopeful that belapectin may be a potential new treatment for the large number of patients in the U.S.
11/14/24 8:00:00 AM ET
$GALT
Biotechnology: Pharmaceutical Preparations
Health Care
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said, "We continued to advance the NAVIGATE Phase 2b/3 trial of belapectin in the first half of 2024. We believe that belapectin can potentially offer a new medical treatment option for the increasing number of patients affected with MASH associated liver cirrhosis and portal hypertensi
8/13/24 8:00:00 AM ET
$GALT
Biotechnology: Pharmaceutical Preparations
Health Care
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH)NAVIGATE trial remains on track for interim top-line readout late in the fourth quarter of 2024 NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "This quarter we remai
5/15/24 8:00:00 AM ET
$GALT
Biotechnology: Pharmaceutical Preparations
Health Care

Galectin Therapeutics Highlights Outcome Of Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study

Chat with this insight

Recent Analyst Ratings for $GALT

$GALT Market Insights

Live Market Insights

Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

Insider Analysis: Purchase at Galectin Therapeutics Inc. on Jun 20

As Of March 31, 2024, Galectin Therapeutics Had $23.6M Of Cash And Cash Equivalents. Additionally, The Company Has $10M Remaining Available Under A $60M Line Of Credit Expected To Provide Cash Runway Into May 2025

$GALT Insider purchases explained

Analytical look into recent insider purchases

Insider Analysis: Purchase at Galectin Therapeutics Inc. on Jun 20

$GALT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Eldred Kary bought $1,300 worth of shares (500 units at $2.60), increasing direct ownership by 1% to 50,213 units (SEC Form 4)

Director Freeman Kevin D bought $3,432 worth of shares (1,300 units at $2.64), increasing direct ownership by 4% to 34,769 units (SEC Form 4)

Director Freeman Kevin D bought $27,000 worth of shares (10,000 units at $2.70), increasing direct ownership by 18% to 33,469 units (SEC Form 4)

$GALT Press Releases

Fastest customizable press release news feed in the world

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

$GALT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on Galectin Therapeutics with a new price target

$GALT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$GALT SEC Filings

Director Eldred Kary bought $1,300 worth of shares (500 units at $2.60), increasing direct ownership by 1% to 50,213 units (SEC Form 4)

Director Freeman Kevin D bought $3,432 worth of shares (1,300 units at $2.64), increasing direct ownership by 4% to 34,769 units (SEC Form 4)

Director Freeman Kevin D bought $27,000 worth of shares (10,000 units at $2.70), increasing direct ownership by 18% to 33,469 units (SEC Form 4)

Galectin Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Galectin Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Galectin Therapeutics Inc.

$GALT Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Galectin Therapeutics Inc. (Amendment)

$GALT Leadership Updates

Live Leadership Updates

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

Galectin Therapeutics Strengthens Leadership Team with Strategic Hires to Advance Programs in Cancer Immunotherapy and NASH Cirrhosis

$GALT Financials

Live finance-specific insights

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

Recent Analyst Ratings for
$GALT

$GALT
Market Insights

$GALT
Insider purchases explained

$GALT
Insider Trading

$GALT
Press Releases

$GALT
Analyst Ratings

$GALT
Insider Purchases

$GALT
SEC Filings

$GALT
Large Ownership Changes

$GALT
Leadership Updates

$GALT
Financials